0001654954-22-000654.txt : 20220119 0001654954-22-000654.hdr.sgml : 20220119 20220119131352 ACCESSION NUMBER: 0001654954-22-000654 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220119 FILED AS OF DATE: 20220119 DATE AS OF CHANGE: 20220119 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GLAXOSMITHKLINE PLC CENTRAL INDEX KEY: 0001131399 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15170 FILM NUMBER: 22537914 BUSINESS ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS BUSINESS PHONE: 011442080475000 MAIL ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS 6-K 1 a0022z.htm DIRECTOR/PDMR SHAREHOLDING a0022z
 
 
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of January 2022
 
Commission File Number 001-15170
 
 
GlaxoSmithKline plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 
 
 
GlaxoSmithKline plc (the 'Company')
Transaction notification
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
a)
 
Name
Ms E Walmsley
b)
 
Position/status
Chief Executive Officer
c)
Initial notification/ amendment
Initial notification
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
 
Name
GlaxoSmithKline plc
b)
 
LEI
5493000HZTVUYLO1D793
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
 
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 January 2022
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£16.9668
 
2,442.981
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
 
Date of the transaction
2022-01-18
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
a)
 
Name
Mr R Connor
b)
Position/status
President, Vaccines & Global Health
 
c)
Initial notification/ amendment
Initial notification
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
 
Name
GlaxoSmithKline plc
b)
 
LEI
5493000HZTVUYLO1D793
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
 
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 January 2022
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£16.9668
 
2,394.998
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
 
Date of the transaction
2022-01-18
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
a)
 
Name
Ms D Conrad
b)
 
Position/status
SVP, Human Resources
c)
Initial notification/ amendment
Initial notification
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
 
Name
GlaxoSmithKline plc
b)
 
LEI
5493000HZTVUYLO1D793
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
 
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 January 2022
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£16.9668
7.914
 
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
 
Date of the transaction
2022-01-18
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
a)
 
Name
Mr J Ford
b)
 
Position/status
SVP & General Counsel
c)
Initial notification/ amendment
Initial notification
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
 
Name
GlaxoSmithKline plc
b)
 
LEI
5493000HZTVUYLO1D793
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
 
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 January 2022
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£16.9668
0.00003
 
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
 
Date of the transaction
2022-01-18
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
a)
 
Name
Ms S Jackson
b)
 
Position/status
SVP, Global Communications and CEO Office
c)
Initial notification/ amendment
Initial notification
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
 
Name
GlaxoSmithKline plc
b)
 
LEI
5493000HZTVUYLO1D793
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
 
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 January 2022
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£16.9668
290.908
 
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
 
Date of the transaction
2022-01-18
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
a)
 
Name
Mr D Jackson
b)
 
Position/status
PCA of Ms S Jackson (SVP, Global Communications and CEO Office)
c)
Initial notification/ amendment
Initial notification
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
 
Name
GlaxoSmithKline plc
b)
 
LEI
5493000HZTVUYLO1D793
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
 
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 January 2022
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£16.9668
127.788
 
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
 
Date of the transaction
2022-01-18
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
a)
 
Name
Mr L Miels
b)
 
Position/status
Chief Commercial Officer
c)
Initial notification/ amendment
Initial notification
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
 
Name
GlaxoSmithKline plc
b)
 
LEI
5493000HZTVUYLO1D793
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
 
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 January 2022
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£16.9668
4,329.944
 
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
 
Date of the transaction
2022-01-18
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
a)
 
Name
Mr D Redfern
b)
 
Position/status
Chief Strategy Officer
c)
Initial notification/ amendment
Initial notification
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
 
Name
GlaxoSmithKline plc
b)
 
LEI
5493000HZTVUYLO1D793
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
 
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 January 2022
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£16.9668
 
3,945.170
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
 
Date of the transaction
2022-01-18
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
a)
 
Name
Mr R Simard
b)
 
Position/status
President, Pharmaceuticals Supply Chain
c)
Initial notification/ amendment
Initial notification
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
 
Name
GlaxoSmithKline plc
b)
 
LEI
5493000HZTVUYLO1D793
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
 
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 January 2022
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£16.9668
704.698
 
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
 
Date of the transaction
2022-01-18
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
a)
 
Name
Mr P Thomson
b)
 
Position/status
President, Global Affairs
c)
Initial notification/ amendment
Initial notification
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
 
Name
GlaxoSmithKline plc
b)
 
LEI
5493000HZTVUYLO1D793
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
 
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 January 2022
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£16.9668
854.670
 
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
 
Date of the transaction
2022-01-18
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
a)
 
Name
Ms K Thomson
b)
 
Position/status
PCA of Mr P Thomson (President, Global Affairs)
c)
Initial notification/ amendment
Initial notification
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
 
Name
GlaxoSmithKline plc
b)
 
LEI
5493000HZTVUYLO1D793
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
 
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 January 2022
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£16.9668
134.426
 
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
 
Date of the transaction
2022-01-18
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
a)
 
Name
Ms D Waterhouse
b)
 
Position/status
Chief Executive Officer of ViiV Healthcare
c)
Initial notification/ amendment
Initial notification
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
 
Name
GlaxoSmithKline plc
b)
 
LEI
5493000HZTVUYLO1D793
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
 
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 January 2022
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£16.9668
172.088
 
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
 
Date of the transaction
2022-01-18
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: January 19, 2022
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc